Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-09-17
|
Jardiance® (empagliflozin) |
type 2 diabetes |
3 |
Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) |
Cardiovascular diseases - Metabolic diseases |
2015-09-16
|
Strensiq™ (asfotase alfa) |
hypophosphatasia |
|
Alexion Pharmaceuticals (USA - CT) |
Rare diseases - Genetic diseases - Metabolic diseases |
2015-09-15
|
ZP-I-98 |
type 2 diabetes |
preclinical |
Zealand Pharma (Denmark) |
Metabolic diseases |
2015-09-15
|
diagnostic method used to identify NASH patients that should be treated with elafibranor (GFT505) |
NASH (non-alcoholic steatohepatitis) |
|
Genfit (France) |
Liver diseases - Hepatic diseases - Diagnostic |
2015-09-15
|
|
hepatic porphyrias, acute intermittent porphyria (AIP), variegate porphyria, and hereditary coproporphyria, suffering from recurrent attacks |
|
Alnylam Pharmaceuticals (USA - MA) the American Porphyria Consortium (USA) The European Porphyria Network |
Genetic diseases - Metabolic diseases - Rare diseases |
2015-09-14
|
autologous bone marrow cells |
multiple sclerosis |
1 |
North Bristol NHS Trust (UK) |
Neurodegenerative diseases |
2015-09-13
|
marizomib, pomalidomide and dexamethasone |
multiple myeloma in relapse, refractory multiple myeloma |
1 |
Triphase Accelerator (Canada - USA - CA) Celgene (USA - NJ) |
Cancer - Oncology |
2015-09-10
|
MN-166 (ibudilast) |
amyotrophic lateral sclerosis |
2 |
Medicinova (USA - CA) |
Neurodegenerative diseases - Rare diseases |
2015-09-10
|
arimoclomol citrate |
Niemann-Pick disease type C |
2-3 |
Orphazyme (Denmark) |
Rare diseases - Genetic diseases |
2015-09-10
|
somavaratan (VRS-317) |
adult growth hormone deficiency |
2 |
Versartis (USA - CA) |
Endocrinological diseases - Hormonal diseases |
2015-09-10
|
DTX101 |
hemophilia B |
1-2 |
Dimension Therapeutics (USA - MA) |
Rare diseases - Genetic diseases - Hematological diseases |
2015-09-10
|
Resolaris® |
facioscapulohumeral muscular dystrophy |
1-2 |
Atyr Pharma (USA - CA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2015-09-09
|
Tedopi® (OSE2101) |
advanced non-small cell lung cancer |
2 |
OSE Pharma (France) now OSE Immunotherapeutics |
Cancer - Oncology |
2015-09-09
|
IFN alpha-Kinoid® (IFN-K) |
systemic lupus erythematosus |
1-2 |
Neovacs (France) |
Autoimmune diseases |
2015-09-09
|
TG-1101 (ublituximab), TGR-1202 and pembrolizumab |
chronic lymphocytic leukemia |
1-2 |
TG Therapeutics (USA - NY) |
Cancer - Oncology |
2015-09-09
|
phage therapy |
Escherichia coli and Pseudomonas aeruginosa skin infections in burn patients |
1-2 |
Ministry of Defence (France) Pherecydes Pharma (France) Clean Cells (France) |
Dermatological diseases - Infectious diseases |
2015-09-09
|
AST-OPC1 (oligodendrocyte progenitor cells) |
spinal cord injury |
preclinical |
Asterias Biotherapeutics (USA - CA) |
Rare diseases - Regenerative medicine |
2015-09-09
|
ZP4207 |
treatment of mild to moderate hypoglycemia in diabetes patients |
1 |
Zealand Pharma (Denmark) |
Metabolic diseases |
2015-09-09
|
GKT137831 |
diabetic nephropathy |
2 |
Genkyotex (Switzerland) |
Metabolic diseases - Renal diseases - Kidney diseases |
2015-09-08
|
PRM-151 (recombinant human pentraxin-2) |
idiopathic pulmonary fibrosis (IPF) |
2 |
Promedior (USA - MA) |
Lung diseases - Respiratory diseases - Rare diseases |